Single Blog

What Are PROTACs and Why Are They So Exciting?

Proteolysis-targeting chimeras (PROTACs) are a disruptive class of small-molecule drugs engineered not to block a protein, but to erase it from the cell. Instead of occupying an active site, a PROTAC functions as a molecular matchmaker, simultaneously binding:

• the disease-driving target protein, and
• an E3 ubiquitin ligase, a key component of the cell’s protein disposal system.

By forcing these two proteins into proximity, the PROTAC promotes formation of a ternary complex (E3 ligase–PROTAC–target). This triggers ubiquitination of the target and its subsequent degradation by the proteasome, while the PROTAC itself is released to repeat the cycle. This catalytic, “event-driven” mechanism breaks with traditional occupancy-based pharmacology and opens new space for targeting proteins once labeled “undruggable.” doi:10.1038/nrd.2019.173

Why Small-Molecule PROTACs Outperform Classic Inhibitors

Compared with conventional small-molecule inhibitors, next-generation PROTACs offer several compelling advantages:

• Access to the undruggable proteome
  Many oncogenic drivers, such as transcription factors and scaffolding proteins, lack well-defined catalytic pockets. PROTACs only require a binding epitope, vastly expanding the druggable target universe. doi:10.1016/j.cell.2020.01.034
• Deep and durable knockdown
  Because one PROTAC molecule can degrade multiple copies of a protein, lower systemic exposure can yield profound and sustained target depletion.
• Built-in resistance management
  Tumors often escape inhibitors through target overexpression or point mutations that weaken binding. PROTACs can degrade mutant proteins or counter simple overabundance by eliminating the protein altogether.
• Full functional silencing
  Degradation removes all activities of a protein—enzymatic and scaffolding—revealing biology that cannot be accessed by partial inhibition alone.

Case Study: ARV-110 and the First Wave of Clinical PROTACs

Targeting the Androgen Receptor with a Molecular Assassin

ARV-110 (bavdegalutamide) is one of the first small-molecule PROTACs to reach the clinic, developed for metastatic castration-resistant prostate cancer (mCRPC). It binds the androgen receptor (AR) and recruits the E3 ligase cereblon, driving potent AR degradation.

Early clinical data are striking: in heavily pretreated mCRPC patients, ARV-110 has achieved meaningful prostate-specific antigen (PSA) declines and radiographic responses, including in tumors carrying resistance-associated AR mutations that blunt the efficacy of standard anti-androgens. Its activity in patients who have failed abiraterone or enzalutamide underscores the power of degradation over mere antagonism. doi:10.1158/2159-8290.CD-20-1665

ARV-110 is part of a rapidly expanding pipeline of oncology-focused degraders targeting estrogen receptor (ER), Bruton’s tyrosine kinase (BTK), BCL-xL, and beyond, signaling a shift from “block the signal” to “remove the node.”

Design Challenges: Turning Bifunctional Molecules into Real Drugs

The promise is enormous, but not every bifunctional molecule becomes a viable PROTAC drug candidate. Key hurdles include:

• Size and physicochemical complexity
  PROTACs are typically larger and more flexible than traditional small molecules, which can compromise oral bioavailability and cell permeability. Medicinal chemists must carefully tune linker length, polarity, and rigidity to maintain drug-like properties. doi:10.1021/acs.jmedchem.9b01230
• Choice of E3 ligase and tissue selectivity
  Most clinical PROTACs currently exploit cereblon or VHL. Expanding the E3 ligase toolbox could enable tissue- or tumor-selective degradation while minimizing off-tumor toxicity. doi:10.1016/j.drudis.2019.01.018
• Engineering productive ternary complexes
  Efficient degradation depends on favorable ternary complex formation, not just binary binding affinity. Subtle geometric and energetic factors dictate whether a PROTAC will act as a molecular assassin or a silent binder. doi:10.1038/nrd.2019.173

AI-Powered PROTAC Design: Data-Driven Molecular Assassins

Artificial intelligence is rapidly reshaping how next-generation PROTACs are discovered and optimized:

• Generative design models propose novel linker architectures and E3 ligase ligands that satisfy multiple constraints—potency, permeability, solubility, and selectivity—in silico.
• Machine-learning predictors trained on degradation datasets estimate ternary complex stability and degradation efficiency for specific target–E3 pairs, guiding chemists toward the most promising designs. doi:10.1016/j.cell.2020.01.034
• Multi-parameter optimization frameworks integrate ADME, safety, and off-target degradation risks early, shortening design–make–test cycles.

Outlook: From First-Generation PROTACs to Precision Degraders

The next generation of small-molecule PROTACs is poised to move beyond proof-of-concept oncology trials into a broader therapeutic landscape, including neurodegeneration and immune-mediated diseases. As structure-based design and AI converge, we are entering an era of precision degraders—molecules tuned to specific mutations, resistance mechanisms, and tissue contexts. The paradigm shift is profound: rather than merely silencing a rogue protein, we can now program small molecules to hunt, tag, and eliminate it, rewriting the rules of drug discovery in the process.

Key References

• Burslem GM, Crews CM. Proteolysis-targeting chimeras (PROTACs) as small-molecule tools and therapeutics. Nat Rev Drug Discov. 2020;19(5):305–322. doi:10.1038/nrd.2019.173
• Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Cell. 2019;181(1):102–114. doi:10.1016/j.cell.2020.01.034
• Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs)—past, present and future. Drug Discov Today. 2019;24(5):1153–1162. doi:10.1016/j.drudis.2019.01.018
• Neklesa TK et al. Discovery of ARV-110, a first-in-class androgen receptor degrading PROTAC for the treatment of prostate cancer. Cancer Discov. 2021;11(6):1514–1529. doi:10.1158/2159-8290.CD-20-1665
• Edmondson SD et al. Challenges of PROTAC design and optimization. J Med Chem. 2019;62(11):5272–5282. doi:10.1021/acs.jmedchem.9b01230